Cyclosporin A Antibody

<strong>Cyclosporin A Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2016470_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 500 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8°C_x000D_ <strong>Keywords:</strong> Cyclosporin A antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, Reich HN, Lafayette R, Aslam N, Appel GB, Zand L, Kiryluk K, Liu L, Cattran DC; MENTOR Trial Investigators. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy Clin J Am Soc Nephrol. 2023 Oct 1;18(10):1283-1293._x000D_ 2: Comparon C, Galicier L, Rebibou JM, Coppo P, Benhamou Y. Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura Eur J Haematol. 2023 Feb;110(2):157-160._x000D_ 3: Weiden PL, Wolf SB, Breitz HB, Appelbaum JW, Seiler CA, Mallett R, Bjorn MJ, Su FM, Fer MF, Salk D. Human anti-mouse antibody suppression with cyclosporin A Cancer. 1994 Feb 1;73(3 Suppl):1093-7._x000D_ 4: Gisbert JP, García MJ, Chaparro M. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review J Crohns Colitis. 2023 Jun 16;17(6):972-994._x000D_ 5: Denesyuk AI, Lundell J, Zav'yalov V, Korpela T. Cyclophilin A and an antibody against cyclosporin A resemble each other in their binding sites Immunol Lett. 1994 Jul;41(2-3):213-6._x000D_ 6: Houschyar KS, Tapking C, Borrelli MR, Puladi B, Ooms M, Wallner C, Duscher D, Pförringer D, Rein S, Reumuth G, Schulz T, Nietzschmann I, Maan ZN, Grieb G, Philipp-Dormston WG, Branski LK, Siemers F, Lehnhardt M, Schmitt L, Yazdi AS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis J Wound Care. 2021 Dec 2;30(12):1012-1019._x000D_ 7: Sanchez-Pernaute O, Romero-Bueno FI, Selva-O'Callaghan A. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia Reumatol Clin (Engl Ed). 2021 Nov;17(9):556-557._x000D_ 8: Altschuh D. Cyclosporin A as a model antigen: immunochemical and structural studies J Mol Recognit. 2002 Sep-Oct;15(5):277-85._x000D_ 9: Demeule M, Wenger RM, Béliveau R. Molecular interactions of cyclosporin A with P-glycoprotein. Photolabeling with cyclosporin derivatives J Biol Chem. 1997 Mar 7;272(10):6647-52._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/8065374">10: Rauffer N, Zeder-Lutz G, Wenger R, Van Regenmortel MH, Altschuh D. Structure-activity relationships for the interaction between cyclosporin A derivatives and the Fab fragment of a monoclonal antibody Mol Immunol. 1994 Aug;31(12):913-22. </a>_x000D_ _x000D_ <strong>Products Related to Cyclosporin A Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>